Abstract library

10 results for "Tafuto".
#735 Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to the 2010 WHO Classification of NET: A Multicentric Study
Introduction: SSAs have recently been demonstrated to have antiproliferative effects in ileal NETs. No data are available on SSA efficacy according to 2010 WHO NET categories.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
#860 Expression and Prognostic Role of CXCR4/CXCL12/CXCR7 and mTOR Pathways in Neuroendocrine Tumors (NETs)
Introduction: The chemokine receptor CXCR4 interacts with the ligand CXCL12 to exert proliferative and chemotactic effects. CXCR4 activates mTOR through phosphorylation of its two effectors downstream:4EBP1and S6K
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Doctor Luisa Circelli
#963 From E.L.I.O.S. (Educational Learning Investigational Observational Study) an Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification
#1000 E.L.I.O.S. (Educational Learning Investigational Observational Study): An Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)
Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: student Concetta Sciammarella
#1452 Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade
Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Salvatore Tafuto
#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Antongiulio Faggiano